Calamos Advisors
NDRM

Calamos Advisors’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Calamos Advisors’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-26,900
Closed -$804K – 664
2017
Q2 		$804K Hold
26,900
– – 0.01% 559
2017
Q1 		$714K Buy
+26,900
New +$666K 0.01% 558

Other funds holding NDRM

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
CFIC
City Financial Investment Company London, United Kingdom $562M AUM 5.93% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Calamos Advisors's NDRM Position: Q3 2017 in Review

Calamos Advisors sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017, closing a stake of 26,900 shares — an estimated $804K sold.

Calamos Advisors first reported a position in NDRM in Q1 2017 and held it in 2 quarters. The position peaked at $804K in Q2 2017. 81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

  • Calamos Advisors reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Calamos Advisors sold 26,900 NeuroDerm Ltd. Ordinary Shares shares in Q3 2017, an estimated $804K.
  • Calamos Advisors first reported a position in NeuroDerm Ltd. Ordinary Shares in Q1 2017 and held it in 2 quarters.
  • Calamos Advisors's NeuroDerm Ltd. Ordinary Shares position peaked at $804K in Q2 2017.
  • 81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on Calamos Advisors's 13F filing for Q3 2017, filed 25 Oct 2017.